Histopathology Confirmed Cases (n = 113) Clinicopathologic Characteristic | Number (%) |
---|---|
Histopathology Method (n = 113) | |
 Core Biopsy | 16 (14%) |
 Surgical Sample | 97 (86%) |
Histopathology Report Time (n = 107)a | |
 Median (range, days) | 36 (1–202) |
  < 1 month | 39 (36%) |
  > 1 month | 68 (64%) |
Treatment Staging: Chest (n = 113) | |
 Chest X-Ray | 10 (9%) |
 Chest CTb | 29 (26%) |
 None | 74 (65%) |
Treatment Staging: Abdomen (n = 113) | |
 Abdominal ultrasound | 48 (42%) |
 Abdominal CT scanc | 27 (24%) |
 None | 38 (34%) |
Nodal Status (n = 113) | |
 Positive | 38 (34%) |
 Negative | 10 (9%) |
 Not reported | 65 (57%) |
Tumor Size (n = 113) | |
  < 2 cm | 3 (3%) |
 2–5 cm | 27 (24%) |
  > 5 cm | 30 (26%) |
 Not reported | 53 (47%) |
Tumor Grade (n = 113) | |
 Grade I | 3 (3%) |
 Grade II | 34 (30%) |
 Grade III | 39 (34%) |
 Not reported | 37 (33%) |
Receptor Status (n = 113) | |
 Hormone Receptor Tested | 10 (9%) |
  ER/PR negative | 4 (40%) |
  ER/PR positive | 5 (50%) |
  ER positive/PR negative | 1 (10%) |
 Hormone Receptor Not tested | 103 (91%) |
 HER2 Receptor Tested | 7 (6%) |
  Positive | 3 (43%) |
  Negative | 4 (57%) |
HER2 Receptor Not tested | 106 (94%) |